Tango Therapeutics, Inc. (TNGX): Capital Expenditures
$1.05M
Year ended 2025-12-31
$351.0K
Trailing 12 months to 2026-06-30
-48.5%
3-year compound annual growth
-1.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.05M | +39.0% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $754.0K | -50.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $1.53M | -80.2% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $7.69M | +318.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.84M | +66.1% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $1.11M | n/a | 2022-03-28, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
| Fortress Biotech, Inc. (FBIO) | 2024-12-31 | $0 | -100.0% |
| Journey Medical Corp (DERM) | 2024-12-31 | $15.00M | +200.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $29.0K | -87.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $495.0K | -3.1% |
Compare TNGX, FBIO, DERM, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗